However, an important challenge was the low referral rate (49.2%) of patients with vivax malaria from the community to the health center where G6PD testing and primaquine were provided; hence, a large proportion (62.9%) of eligible patients did not receive radical curative treatment. This evidence concerns the gene G6PD and Plasmodium vivax malaria.